In March, pharmaceutical company Cassava Sciences made headlines for a report by the Food and Drug Administration (FDA) that cast doubt on the positive trial results of its novel Alzheimer’s drug, simufilam. Then, in September, the Securities and Exchange Commission (SEC) settled with Cassava…
Continue reading...